ClinicalTrials.gg
Status unknownNCT03369262PROLONGUpdated Jun 7, 2021

PoC Study of OBE022 in Threatened Preterm Labour

A Phase 2 interventional study of OBE022 and Placebos in Preterm Labor, sponsored by ObsEva SA. Status unknown at 18 sites in 6 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-07.

Sponsored by ObsEva SA · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jun 2021), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
115
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Obstetric Labor, Premature with a site in Israel — 1 open to participants now, 1 under way, none of them phase 3. Obstetric Labor, Premature · Israel.

Started
2018
with 1 other
Phase 2
Only one
of the 13
Registered
11th of 13
by date
Lead sponsor
1 of 13
ObsEva SA

Among the 13 studies in Obstetric Labor, Premature with a site in Israel, this one is one of 2 that started in 2018, is the only one in phase 2, and was the 11th registered.

Obstetric Labor, Premature

243 studies on the registry are indexed under Obstetric Labor, Premature; 36 are open to participants now.

Browse Obstetric Labor, Premature studies →

Open to participants now

1 of the 13 studies in Obstetric Labor, Premature with a site in Israel is open now. Recruiting first, the newest first:

A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →

Who these studies take

Of the 24 Obstetric Labor, Premature studies recruiting now, 14 (58%) set no upper age limit and 9 (38%) stop at 75 or younger; 5 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Obstetric Labor, Premature with a site in Israel, or all of them as a file.
02

Study summary

This is a proof-of-concept study in 2 parts.

In Part A, patients will receive OBE022 open-label in order to assess the safety and pharmacokinetics in pregnant women with spontaneous preterm labour with a gestational age between 28 0/7 and 33 6/7 weeks.

Part B has a double-blind, randomised, placebo controlled, parallel group and multicentre design and will assess the efficacy, safety and pharmacokinetics in pregnant women with threatened spontaneous preterm labour with a gestational age between 24 0/7 and 33 6/7 weeks.

All patients in part A and part B must receive atosiban infusion for 48 hours as standard of care treatment. Patients from Part A will receive OBE022 open label. Patients from Part B will be randomised to receive OBE022 or matching placebo. IMP treatment duration will be up to 7 days. IMP treatment will be stopped in case of delivery prior to Day 7.

03

Conditions studied

  • Preterm Labor

Keywords

  • preterm labor
  • preterm birth
  • premature birth
  • tocolysis
  • prostaglandin F2α antagonist
  • PGF2α
  • tocolytic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

Part A

  • Pregnant females aged ≥ 18 years
  • Patients with a singleton or twin pregnancy
  • Gestational age between 28 0/7 and 33 6/7
  • Administered or prescribed atosiban for the treatment of preterm labour

Part B

  • Pregnant females aged ≥ 18 years
  • Patients with a singleton or twin pregnancy
  • Gestational age between 24 0/7 and 33 6/7
  • Administered or prescribed atosiban for the treatment of preterm labour
  • ≥4 uterine contractions per 30 minutes
  • Cervical dilatation of 1 to 4 cm inclusive
  • At least one of the following signs of preterm labour:

    1. positive IGFBP-1 or fœtal Fibronectin test
    2. cervical length ≤ 25mm
    3. progressive cervical change

Key Exclusion Criteria:

  • Fœtal death in utero in current or previous pregnancy after gestational week 24 or expected high risk of fœtal death in the coming days
  • Oligohydramnios
  • Known pathological Doppler ultrasound of the umbilical artery
  • Any for the mother or the fœtus to stop labour or prolong pregnancy or any maternal or fœtal conditions likely to indicate iatrogenic delivery in the next 7 days, including but not limited to:

    1. Premature rupture of membranes
    2. Evidence or suspicion of abruptio placenta
    3. Signs and/or symptoms of chorio-amnionitis
    4. Pre-eclampsia, eclampsia or HELLP-syndrome
  • Use of cervical cerclage in the current pregnancy or a pessary in situ
  • Current use of anti-hypertensive medication
  • Treatment with other tocolytics within specified time before the baseline assessment of uterine contractions
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
115 participants (actual)

Study arms

  • Experimental
    Active

    OBE022 plus atosiban: OBE022 will be given orally from Day 1 to Day 7. OBE022 treatment will be initiated ideally simultaneously or at a maximum within 24 h after atosiban start. * Loading dose: 1 000 mg on Day 1. * Maintenance dose on Day 1: 500 mg in the evening if loading dose was administered in the morning. If loading dose was administered in the afternoon, then the next dose will take place on the morning of Day 2. * Maintenance dose from Day 2 to Day 7: 500 mg twice a day (only morning dose on Day 7) Atosiban will be administered over 48h as per label.

    Drug: OBE022 · Drug: Atosiban

  • Active comparator
    Placebo

    OBE022 matching placebo plus atosiban: OBE022 matching placebo administration will follow the same regimen as the active group. Atosiban will be administered over 48h as per label.

    Drug: Placebos · Drug: Atosiban

Interventions

  • DrugOBE022

    Oral

  • DrugPlacebos

    Oral

  • I.V.

06

What researchers measure

Primary outcomes

  1. Incidence of delivery within 2 days (48 h) from start of IMP administration

    Time frame: 48 hours

  2. Incidence of delivery within 7 days (168 h) from start of IMP administration

    Time frame: 168 hours

  3. Incidence of delivery before 37 weeks of GA

    Time frame: Up to 13 weeks from start of IMP administration

  4. Time to delivery measured from start of IMP administration

    Time frame: Up to 17 weeks from start of IMP administration

Other outcomes

  1. Maternal incidence of AEs from Day 1 until 28 days after birth.

    Time frame: 28 days after birth

  2. Maternal incidence of TEAEs from Day 1 until 28 days after birth.

    Time frame: 28 days after birth

  3. Maternal incidence of clinically significant changes in laboratory safety tests, from Day 1 until 28 days after birth.

    Time frame: 28 days after birth

  4. Maternal incidence of clinically significant changes in vital signs, from Day 1 until 28 days after birth.

    Time frame: 28 days after birth

  5. Incidence of AEs indicating fœtal distress such as growth retardation and/or changes in fœtal heart rate monitoring and/or amniotic fluid index (AFI) from Day 1 to Day 7 and Day 14 (or earlier if birth).

    Time frame: Up to 14 days after start of IMP administration

  6. In Part A only: Incidence of fœtal adverse events in relation with the cardiovascular function assessed by Doppler ultrasound on Day 1 to 3 and Day 7 from IMP start.

    Time frame: Up to 7 days after start of IMP administration

  7. Incidence of infants experiencing adverse events from birth until 28 days after birth.

    Time frame: Up to 28 days after birth

  8. Incidence of infants experiencing clinical significant changes in vital signs from birth until 28 days after birth.

    Time frame: Up to 28 days after birth

  9. Apgar score.

    The score is a rapid method for assessing a neonate immediately after birth. Elements of the Apgar score include color, heart rate, reflexes, muscle tone, and respiration, each weighted evenly and assigned a value of 0, 1, or 2. The components are then added together to give a total score (0 to 10) that is recorded at 1 and 5 minutes after birth.

    Time frame: At birth, at 1 minute and 5 minute

  10. Weight.

    Time frame: At birth and 28 days after birth.

  11. Head circumference.

    Time frame: At birth and 28 days after birth.

  12. Incidence of infants experiencing prematurity-related events

    Time frame: At birth.

  13. Incidence of duration of hospitalization and or re-admission to hospital.

    Time frame: Up to 28 days after birth.

  14. Incidence of infants with one or more Ages and Stages Questionnaire® domain score(s) below the cut-off score at 6 months, 12 months and 24 months of age, adjusted for gestational age at birth.

    The Ages and Stages Questionnaire (ASQ) is a parent-completed questionnaire designed to be used as a general developmental screening tool. The ASQ-3 covers five areas of child development that includes: personal social, gross motor, fine motor, problem solving, and communication. Parents complete the questionnaire independent of professionals, indicating for each item "yes" if child performs the item, "sometimes" indicating an occasional or emerging skill, or "not yet" indicating that the child does not yet perform the behavior

    Time frame: Up to 24 months

  15. Plasma concentration of OBE022/OBE002 at Day 1, Day 2, Day 3 and Day 7.

    Time frame: Up to 7 days after start of IMP administration

  16. Pharmacokinetic parameters of OBE022/OBE002 at Day 7

    Area under the curve (AUC)

    Time frame: Day 7

  17. Pharmacokinetic parameters of OBE022/OBE002 at Day 7

    Maximal concentration (Cmax)

    Time frame: Day 7

  18. Pharmacokinetic parameters of OBE022/OBE002 at Day 7

    Half-life.

    Time frame: Day 7

  19. Fœtal (cord blood)-maternal OBE002 concentration ratio at the time of delivery for patients who received IMP treatment within the previous 24 h.

    Time frame: Day of delivery

  20. Changes in uterine contractions as assessed by electrohysterography, tocodynamometry or abdominal palpation at each hour during the first 6 hours after IMP start.

    Time frame: Up to 6 hours after IMP start.

07

Study locations

18 sites
  • Gynekologicko-porodnická klinika Fakultní nemocnice Brno
    Brno, Czechia
  • Gynekologicko-porodnická klinika 1. LF UK a VFN v Praze
    Praha, Czechia
  • Ústav pro péči o matku a dítě
    Praha, Czechia
  • Helsinki Universisty Hospital
    Helsinki, Finland
  • Hilel Yafe Medical Center, Maternal Fetal Unit
    Haifa, Israel
  • Rambam Medical Center, Maternal Fetal Unit
    Haifa, Israel
  • Meir Medical Center, Obstetrics and Gynecology Department
    Kfar Saba, Israel
  • Rabin Medical Center, Fetal-Maternal Medicine, Helen Schneider's Hospital for Women
    Petah tikva, Israel
  • Moscow Regional Perinatal Center
    Balašicha, Russian Federation
  • Kazan State Medical University
    Kazan, Russian Federation
  • City clinical hospital № 15 named after O. M. Filatov of Healthcare Department of Moscow
    Moscow, Russian Federation
  • Perinatal center of the City Clinical Hospital #24
    Moscow, Russian Federation
  • Hospital La Paz
    Madrid, Spain
  • Hospital Clínico Universitario Virgen de la Arrixaca
    Murcia, Spain
  • Hospital Clínico Universitario de Santiago
    Santiago De Compostela, Spain
  • Hospital Universitari i Politècnic La Fe
    Valencia, Spain
  • Hanoi Obstetrics and Gynecology Hospital
    Hanoi, Vietnam
  • My Duc Hospital
    Ho Chi Minh City, Vietnam
08

References and documents

Publications

  • Wilson A, Hodgetts-Morton VA, Marson EJ, Markland AD, Larkai E, Papadopoulou A, Coomarasamy A, Tobias A, Chou D, Oladapo OT, Price MJ, Morris K, Gallos ID. Tocolytics for delaying preterm birth: a network meta-analysis (0924). Cochrane Database Syst Rev. 2022 Aug 10;8(8):CD014978. doi: 10.1002/14651858.CD014978.pub2. PubMed 35947046 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2018 to primary completion in Jul 2020, 29 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2017
First posted
Dec 11, 2017
StartActual
Jan 10, 2018
Primary completionActual
Jul 8, 2020
CompletionEst.
Aug 2022
Last update
Jun 7, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 7, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03369262
Lead sponsor
ObsEva SA
Collaborators
Scope International AG, Iqvia Pty Ltd, Cytel Inc., PhinC Development
Responsible party
Sponsor
First posted
Dec 11, 2017
Start date
Jan 10, 2018
Primary completion
Jul 8, 2020
Completion
Aug 2022 (estimated)
Last update
Jun 7, 2021

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion